west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "XING Wang" 1 results
  • Comparison on Clinical Outcomes Between China-made CL-V Bileaflet Prosthesis and St. Jude Bileaflet Prosthesis

    Abstract: Objective To evaluate early clinical outcomes and short-term follow-up results of CL-V bileaflet prosthesis. Methods From April 2004 to May 2010, 38 patients with valvular heart diseases underwent mechanical heart valve replacement. Eighteen patients received CL-V bileaflet valve replacement (CL group) including 8 males and 10 females with their mean age of (47.4±6.2)years and mean body weight of (64.7±11.9) kg. Preoperatively,15 patients were in New York Heart Association (NYHA) classⅢ, and 2 patients were in NYHA classⅣ. Mitral valve replacement (MVR) was performed in 16 patients, mitral and aortic valve replacement(DVR) in 2 patients. A total of 20 CL-V bileaflet prostheses were implanted. Twenty patients received St. Jude bileaflet valve replacement (SJM group)including 9 males and 11 females with their mean age of (49.7±7.6) years and mean body weight of (66.1±11.1) kg. Preoperatively, 15 patients were in NYHA classⅢ, and 3 patients were in NYHA classⅣ. MVR was performed in 17 patients,aortic valve replacement (AVR) in 1 patient, and DVR in 2 patients. A total of 22 St. Jude bileaflet prostheses were implanted. Clinical outcomes, hear function, hemodynamics and blood compatibility were measured on the 7th postoperative day and 6 months during follow-up and compared between the two groups. Results There was no early mortality (<30 d) or postoperative complication in either group. Follow-up rate was 100% and the mean follow-up duration was 19.8 (6-61)months. At 6 months after surgery, those patients who were preoperatively in NYHA classⅢ orⅣall improved to classⅠ orⅡ. In CL group, cardiothoracic ratio was 0.51±0.05, left atrium diameter (44.5±7.8) mm, left ventricular end diastolic diameter (LVEDD,46.6±4.1) mm, LVEF 65.3%±7.7%,and LVFS 35.0%±7.1%. In SJM group, cardiothoracic ratio was 0.51±0.06, left atrium diameter (45.8±9.6) mm, LVEDD (46.2±9.8) mm, LVEF 64.1%±9.0%,and LVFS 34.9%±4.7%, which were not statistically different from those parameters of CL group respectively (P>0.05). At 6 months after surgery, transthoracic echocardiography was used to compare hemodynamics of bileaflet prostheses with same size 27 mm in the two groups. Prosthetic transvalvular gradient was (5.1±0.9)mm Hg in CL group and (5.8±0.8) mm Hg in SJM group, and effective orifice area was (2.3±0.3)cm2 in CL group and(2.5±0.2)cm2 in SJM group,which were not statistically significant between the two groups (P>0.05) respectively. In both groups, the level ofhemoglobin, lactate dehydrogenase and platelet at 6 months postoperatively were all within normal range and not statistically from those respective preoperative parameters(P>0.05). Hemolytic reaction and hemolytic anemia were not found. During early and short-term follow-up, there was no thromboembolic complications or anticoagulation-related severe bleeding events in the two groups with same anticoagulation intensity target (target INR value 1.5 to 2.5). Conclusion Early clinical outcomes and short-term follow-up results of CL-V bileaflet prostheses are similar to those of St. Jude bileaflet prostheses. Postoperative patients have good clinical outcomes, hemodynamics and blood compatibility. Patients’ heart function significantly improve during short-term follow-up without valve-related complication. Mid-term and Long-term follow-up are further needed to demonstrate its good performance.

    Release date:2016-08-30 05:50 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content